Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wide Data Gap On Generics Use In Japan Puts Damper On MHLW 30% Generic Target

This article was originally published in PharmAsia News

Executive Summary

TOKYO - A wide data gap on generics penetration between studies commissioned by Chuikyo and the Ministry of Health, Labor and Welfare has surfaced, casting clouds over the Japanese government's official target to raise generics use to 30 percent by 2012

You may also be interested in...



Frustration Drives Japan To Allow Generics Before Side Patents Expire

TOKYO - In a continuing effort to raise generic drug use, Japan's Ministry of Health, Labor and Welfare has decided to allow generic drugs to be manufactured even before brand drugs' side patents expire, the ministry's Insurance Bureau officials said

Frustration Drives Japan To Allow Generics Before Side Patents Expire

TOKYO - In a continuing effort to raise generic drug use, Japan's Ministry of Health, Labor and Welfare has decided to allow generic drugs to be manufactured even before brand drugs' side patents expire, the ministry's Insurance Bureau officials said

Teva-Kowa Faces Uphill Battle With Japanese Domestic And Foreign Generic Drug Makers

Beginning in April, a new joint venture between generic firm Teva and Kowa, a mid-sized Japanese drug maker, will make its official debut in Japan. Aiming to generate ¥100 billion in sales by 2015 and thus becoming the leading generic drug maker in Japan, Teva-Kowa Pharma could drastically change the fast-growing - and yet still lagging - Japanese generic drug market

Related Content

UsernamePublicRestriction

Register

SC071227

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel